Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Assembly Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211987
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Proceeds from maturities of marketable securities | 57,600 | 26,432 |
| Purchases of marketable securities | (62,963) | (19,846) |
| Purchases of property and equipment | (19) | — |
| Net cash (used in) provided by investing activities | (5,382) | 6,586 |
| Cash flows from financing activities | ||
| Proceeds from the issuance of common stock under ATM equity offering program, net of issuance costs | — | 1,922 |
| Proceeds from the exercise of stock options | 149 | — |
Item 1. Financial Statements
FAQ
- What is Assembly Biosciences's capex?
- Assembly Biosciences (ASMB) reported capex of $19K in Q1 2026.
- What is the long-term trend for Assembly Biosciences's capex?
- Over 2 years (2022 to 2025), Assembly Biosciences's capex has grown at a -19.6% compound annual growth rate (CAGR), from $102K to $66K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Assembly Biosciences's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude